http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
박승용 경인행정학회 2014 한국정책연구 Vol.14 No.3
「출입국․외국인정책 통계월보(2014년 7월호)」(법무부 출입국․외국인정책본부, 2014. 8)에 따르면, 2014년 7월 31일 현재 우리나라 결혼이민자 수는 151,696명이며, 이 가운데 여성은 129,233명으로 약 85.3%를 차지하고 있다. 코리안 드림을 꿈꾸며 한국으로 결혼이주 한 여성들은 한국인으로 정착하여 한국에 기여할 중요한 인적 자원이며, 동시에 고귀한 인격체이다. 그러나 이러한 국제결혼이주여성은 법적․제도적으로 여러 면에서, 그리고 사회적 차별 속에서 고통을 받는 경우가 많다. 본 연구에서는 국제결혼이주여성에 관한 법적․제도적 고찰을 통해, 국제결혼이주여성에 관련된 법제의 문제점과 개선방안들을 고찰하고자 하였다. 이를 위해 결혼이주여성과 관련하여 제기된 일반적인 문제점들을 한국여성인권진흥원에서 발간한 자료를 중심으로 살펴보았고, 구체적으로 국적법․다문화가족지원법․결혼중개업의 관리에 관한 법률․재한외국인 처우 기본법․출입국관리법 등을 중심으로 법적․제도적 문제점을 고찰하였으며, 그 동안 여러 문제점들이 제기되어 상당 부분 바람직한 방향으로 개선되어 왔으나, 아직 미진하다고 생각되는 문제점들을 중심으로 바람직한 개선방안을 찾아보고자 하였다.
P-122 Effectiveness and Safety of Tolvaptan for the Management of Hyponatremia
박승용,박미선,안효초,범진선,김주신,박성주,이흥범 대한결핵 및 호흡기학회 2017 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.124 No.0
Background: Hyponatremia is the most common electrolyte disturbance in hospitalized patients and has been associated with increased morbidity and mortality. Tolvaptan, a vasopressin receptor antagonist, is increasingly used to treat euvolemic and hypervolemic hyponatremia. The aim of this study was to evaluate the effectiveness and safety of tolvaptan for the management of hyponatremia. Methods: This study was a retrospective evaluation of 106 patients who received at least one dose of tolvaptan for hyponatremia at a tertiary academic university hospital between January 2014 and June 2015. Results: The mean initial dose of tolvaptan was 20.2 ± 7.2 mg and the duration of treatment was 15 (range 1 - 261) days. The maximal changes in sodium levels at 24 and 48 h were 8.2 ± 4.7 mmol/L and 10.5 ± 15.3 mmol/L, respectively, from a mean baseline of 124.4 ± 5.1 mmol/L. Of 99 patients in whom sodium concentrations were followed up, sodium overcorrection was observed in 26 (26.3%) patients, which was associated with concomitant use of a hypertonic solution (odds ratio [OR] = 1.05, 95% confidence interval [Cl]: 1.01-1.10) and treatment with an initial high dose (OR = 4.50, 95% Cl: 1.05-19.31) and an enzyme inhibitor (OR = 3.7, 95% Cl: 1.08-12.75). The most commonly reported side effects were mild and related to aquaresis, such as polyuria, thirst, and constipation. Conclusion: Tolvaptan is effective for treating hyponatremia. However, careful use is necessary due to serious side effects related to sodium overcorrection.
박승용,정재석,최영훈,김소리,박성주,이용철,이흥범 대한결핵 및 호흡기학회 2018 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.126 No.-
Background: The objective of this study is to determine the agreement between stroke volume variation (SVV) measured simultaneously by the FloTracⓇ/VigileoⓇ system and BioZⓇ system to assess fluid status in patients with sepsis or septic shock. Methods: In this retrospective observational study, we evaluated the medical records of patients who monitored by stroke volume variance parameters measured simultaneously by the FloTracⓇ/VigileoⓇ system and BioZⓇ system in patients with sepsis or septic shock in the medical intensive care unit at a tertiary university-affiliated hospital, from June 2017 to January 2018. Results: Total 14 patients with sepsis or septic shock were analyzed. There were no significant correlations between central venous pressure and SVVs measured by the FloTracⓇ/VigileoⓇ and BioZⓇ (CVP vs. SVV (the FloTracⓇ/VigileoⓇ); r=-0.063, P=0.488, CVP vs SVV (BioZⓇ); r=-0.199, P=0.027, SVV (the FloTracⓇ/VigileoⓇ) vs SVV (BioZⓇ); r=0.048, P=0.597). And there was no agreement between central venous pressure and SVVs measured by the FloTracⓇ/VigileoⓇ and BioZⓇ (CVP vs. SVV (the FloTracⓇ/VigileoⓇ); kappa=0.057 (95% CI -0.010~0.214), CVP vs SVV (BioZⓇ); kappa=0.039 (95% CI -0.009~0.087), SVV (the FloTracⓇ/VigileoⓇ) vs SVV (BioZⓇ); kappa=0.005 (95% CI -0.103~0.112). Conclusion: Our preliminary study showed disagreement the hemodynamic parameters measured by one of the two devices and it should be interpreted with caution before therapeutic interventions.